RASP — Actavia Life Sciences Share Price
0.000.00%
Last trade - 00:00- $6.02m
- $6.23m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
Directors
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 6th, 2012
- Public Since
- March 28th, 2014
- No. of Shareholders
- 49
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 771,811,360
- Address
- 420 Lexington Ave Ste 2525, NEW YORK, 10170-2599
- Web
- https://www.rasna.com/
- Phone
- +1 6463964087
- Auditors
- Mazars USA LLP
Upcoming Events for RASP
Q3 2024 Actavia Life Sciences Inc Earnings Release
Similar to RASP
Acorda Therapeutics
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Actavia Life Sciences share price?
As of Today at 19:00 UTC, shares in Actavia Life Sciences are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Actavia Life Sciences share price performed this year?
Shares in Actavia Life Sciences last closed at $0.01 and the price had moved by -2.5% over the past 365 days. In terms of relative price strength the Actavia Life Sciences share price has underperformed the S&P500 Index by -13.98% over the past year.
What are the analyst and broker recommendations for Actavia Life Sciences?
There is no consensus recommendation for this security.
What is the Actavia Life Sciences dividend yield?
Actavia Life Sciences does not currently pay a dividend.
Does Actavia Life Sciences pay a dividend?
Actavia Life Sciences does not currently pay a dividend.
When does Actavia Life Sciences next pay dividends?
Actavia Life Sciences does not currently pay a dividend.
How do I buy Actavia Life Sciences shares?
To buy shares in Actavia Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Actavia Life Sciences?
As of the previous close price of $0.01, shares in Actavia Life Sciences had a market capitalisation of $6.02m.
Where are Actavia Life Sciences shares listed?
Here are the trading details for Actavia Life Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RASP
What kind of share is Actavia Life Sciences?
Based on an overall assessment of its quality, value and momentum Actavia Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Actavia Life Sciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Actavia Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actavia Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -12.67%.
As of the last closing price of $0.01, shares in Actavia Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Actavia Life Sciences PE Ratio?
The Actavia Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Actavia Life Sciences?
Actavia Life Sciences' management team is headed by:
- Willy Simon - NEC
- Keeren Shah - FID
- John Brancaccio - IND
- Gary Jacob - IND